Please assess the completion status of the following clinical trial:

Trial Title: Study Of SU011248 Plus Gefitinib (Iressa) In Patients With Advanced Renal Cell Carcinoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed renal cell carcinoma with metastases~* Evidence of unidimensionally measurable disease~* Failure of 1 prior immunotherapy or no prior systemic therapy for metastatic RCC~Exclusion Criteria:~* RCC without any clear (conventional) cell component~* History of or known brain metastases~* Uncontrolled hypertension or other significant cardiac events within the 12 months prior to study entry

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sunitinib + Gefitinib (Type: EXPERIMENTAL): Phase 1 - 37.5 mg Sunitinib 4/2 Schedule + 250 mg Gefitinib; 50 mg Sunitinib + 250 mg Gefitinib~Phase 2 - 37.5 mg Sunitinib 4/2 Schedule + 250 mg Gefitinib

Based on this trial design, predict the completion outcome and termination type (if applicable).